SM

Sabby Management Portfolio holdings

AUM $13M
1-Year Return 26.95%
This Quarter Return
-4.91%
1 Year Return
-26.95%
3 Year Return
-56.43%
5 Year Return
-61.92%
10 Year Return
-71.17%
AUM
$497M
AUM Growth
+$197M
Cap. Flow
+$7.35M
Cap. Flow %
1.48%
Top 10 Hldgs %
59.18%
Holding
270
New
61
Increased
50
Reduced
41
Closed
46

Sector Composition

1 Healthcare 48.01%
2 Consumer Staples 0.23%
3 Technology 0.19%
4 Industrials 0.18%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Shares
Change %
Capital Flow
NURO
151
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$154K 0.01%
132
-381
-74% -$445K
TRIL
152
DELISTED
Trillium Therapeutics Inc.
TRIL
$131K 0.01%
+14,137
New +$131K
KTOVW
153
DELISTED
Kitov Pharma Ltd. Warrants
KTOVW
$126K 0.01%
114,720
ALBO
154
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
$118K 0.01%
11,917
-37,441
-76% -$371K
BNTCW
155
DELISTED
Benitec Biopharma Limited
BNTCW
$100K 0.01%
99,555
CBAY
156
DELISTED
Cymabay Therapeutics
CBAY
$91K ﹤0.01%
67,534
-526,366
-89% -$709K
EYEGW
157
DELISTED
Eyegate Pharmaceuticals, Inc. Warrants
EYEGW
$49K ﹤0.01%
65,393
-108,757
-62% -$81.5K
CLRBW
158
DELISTED
Cellectar Biosciences, Inc.
CLRBW
$47K ﹤0.01%
+65,362
New +$47K
IMNN icon
159
Imunon
IMNN
$14.4M
$27K ﹤0.01%
7
RNVA
160
DELISTED
Rennova Health, Inc.
RNVA
$23K ﹤0.01%
68
+1
+1% +$338
OPXAW
161
DELISTED
Opexa Therapeutics, Inc.
OPXAW
$2K ﹤0.01%
+34,097
New +$2K
AAPL icon
162
Apple
AAPL
$3.56T
0
ABBV icon
163
AbbVie
ABBV
$376B
-46,166
Closed -$2.74M
AFMD
164
DELISTED
Affimed
AFMD
-5,677
Closed -$404K
AKBA icon
165
Akebia Therapeutics
AKBA
$801M
0
AVDL
166
Avadel Pharmaceuticals
AVDL
$1.46B
-12,100
Closed -$148K
BCRX icon
167
BioCryst Pharmaceuticals
BCRX
$1.74B
-165,529
Closed -$1.71M
BHC icon
168
Bausch Health
BHC
$2.67B
0
BLUE
169
DELISTED
bluebird bio
BLUE
-3,509
Closed -$2.92M
BMY icon
170
Bristol-Myers Squibb
BMY
$95B
0
CLDX icon
171
Celldex Therapeutics
CLDX
$1.51B
0
CYTK icon
172
Cytokinetics
CYTK
$5.95B
0
EW icon
173
Edwards Lifesciences
EW
$47.5B
-18,321
Closed -$482K
EXEL icon
174
Exelixis
EXEL
$10.1B
0
GILD icon
175
Gilead Sciences
GILD
$140B
0